Rapamycin (sirolimus, rapamune).
Rapamycin is a novel immunosuppressive agent that is undergoing clinical trials for use in allograft rejection therapy. This paper reviews its in-vitro biological properties, the current state of knowledge concerning its mechanism of action, and its therapeutic applications.
Sehgal
S N
SN
Division of Endothelial Cell and Cytokine Biology, Wyeth-Ayerst Research, Princeton, New Jersey, USA.
Camardo
J S
JS
Scarola
J A
JA
Maida
B T
BT
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000096:biosynthesis; D006084:Graft Rejection / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects; D011090:Polyenes / Q000494:pharmacology* / Q000627:therapeutic use; D020123:Sirolimus
D016207:Cytokines; D007166:Immunosuppressive Agents; D011090:Polyenes; D020123:Sirolimus